Brought to you by 
Genocea Biosciences closes $35mm Series B
07 Jan 2011
Executive Summary
Vaccines developer Genocea Biosciences Inc. has raised $35mm in its Series B financing round. First-time backers Johnson & Johnson Development Corp., Skyline Ventures (adds a board member), and MP Healthcare Venture Management were joined by returning shareholders Polaris Venture Partners, Lux Capital Management, SR One, Cycad Group, Auriga Partners, and Morningside Ventures. Funds will support ongoing pipeline development, including the initiation of clinical trials for Genocea's lead vaccine candidate for herpes simplex virus Type 2. The company's early-2009 Series A brought in $23mm.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genocea Biosciences closes $35mm Series B
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice